Blood disorders
Lymphoma in Tianjin
天津 淋巴瘤
4 hospitals in Tianjin
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Tianjin may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 56 papers led
- 34 papers led
- 21 papers ledNo open trial led
- 7 papers led
Lymphoma in every city Tianjin on the disease page, with the national map
open trials on lymphoma with a hospital in Tianjin
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Tianjin as lead sponsor or study site. 42 of them are led by a hospital in Tianjin. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 4
- Started
- 2026-03
- Posted
- Registry
- NCT07218341
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou
- RecruitingCRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07397832
Age 60 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingExploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07441993
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou
- RecruitingMosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07555470
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingR-PMDT Regimen in Newly Diagnosed PCNSL
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07604987
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07606937
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin
- RecruitingA Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07609862
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingPhase I Study of FXS0683 in the Treatment of Blood Tumors
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07616089
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingGlofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06570447
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06717347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen
- RecruitingUB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
- Phase
- Phase 1
- Started
- 2025-04
- Posted
- Registry
- NCT06743503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin
- RecruitingClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06829771
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou
- RecruitingClinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06830031
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingNewly-diagnosed Pediatric T-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06855810
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan
- RecruitingA Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06914037
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingGT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06948981
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingBispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06996132
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingClinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07106723
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07106749
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitinguCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07109518
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07139873
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin
- RecruitingSupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07153068
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingZanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07165769
Age 18 years to 80 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingPA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07188610
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingAn Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07200375
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- Phase
- Early phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07205315
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingMulticenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07259070
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingObinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07261163
Age 18 years to 80 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07283796
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingZanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07299149
Age 18 years to 90 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingTGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06206174
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingGVM±R in Patients With Relapsed or Refractory Aggressive NHL.
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06244368
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
- Phase
- N/A
- Started
- 2024-02
- Posted
- Registry
- NCT06355739
Age 3 years to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06387121
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingTargeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06395870
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteHefei, Tianjin
- RecruitingStudy Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06445517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Tianjin
- RecruitingCD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06479356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingLinperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06489808
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingPI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06530550
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06566586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingR-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06594640
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingA Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06615193
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Suzhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingRadiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06704555
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- RecruitingJAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06716658
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingThe Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06911710
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05800977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingChidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05958719
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingPhase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2023-09
- Posted
- Registry
- NCT06047197
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Phase
- Phase 1
- Started
- 2022-03
- Posted
- Registry
- NCT05091424
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Nanchang, Tianjin
- RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase
- Phase 3
- Started
- 2022-07
- Posted
- Registry
- NCT05254743
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingA Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
- Phase
- Phase 1
- Started
- 2022-08
- Posted
- Registry
- NCT05341557
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesTianjin
- RecruitingPediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2022-08
- Posted
- Registry
- NCT05660473
Age 14 years to 60 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingObinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05846750
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingObinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
- Phase
- Not given
- Started
- 2022-11
- Posted
- Registry
- NCT05846763
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT05006716
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
- RecruitingSafety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT06021678
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesJinan, Tianjin, Zhengzhou
- RecruitingA Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT06189391
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- RecruitingStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 1/Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04494503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan
- RecruitingPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Started
- 2020-10
- Posted
- Registry
- NCT04586478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou
- RecruitingNational Longitudinal Cohort of Hematological Diseases
- Phase
- Not given
- Started
- 2020-12
- Posted
- Registry
- NCT04645199
Age not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingEvaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07539610
Age 18 years to 69 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07585747
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesJinan, Nanchang, Shenzhen, Tianjin, Zhengzhou
- Not yet recruitingA Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07676175
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Xi'an
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingSCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07819188
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingPirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
- Phase
- Phase 2
- Started
- 2026-12
- Posted
- Registry
- NCT07944651
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
- Not yet recruitingEvaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06845241
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Nanchang, Tianjin, Zhengzhou
- Not yet recruitingBR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07008053
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 5 listed hospitals as study sitesChangsha, Fuzhou, Jinan, Qingdao, Shijiazhuang, Tianjin
- Not yet recruitingA Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07034508
Age 18 years to 80 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07068906
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingEvaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07187960
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou
- Not yet recruitingChemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07206264
Age 60 years to Not stated (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 3 listed hospitals as study sitesFuzhou, Harbin, Jinan, Tianjin
- Not yet recruitingA Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- Phase
- Phase 1
- Started
- 2025-11
- Posted
- Registry
- NCT07234045
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingA First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06318884
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Zhengzhou
- Not yet recruitingReal World Study of Linperlisib for Lymphoma Treatment
- Phase
- Not given
- Started
- 2023-05
- Posted
- Registry
- NCT05863871
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 1 listed hospital as study siteShanghai, Tianjin
- Enrolling by invitationA Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT07784309
Age 3 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Enrolling by invitationAC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
- Phase
- Phase 3
- Started
- 2023-01
- Posted
- Registry
- NCT05678933
Age 18 years to 70 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & HospitalTianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Tianjin
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Logistics University of Chinese People中国人民武装警察部队特色医学中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beichen District Tradicine Chinese Medicine Hospital天津市北辰区中医医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Cangzhou Central Hospital沧州市中心医院 | 2 | none | none | 11 | 30 | none | 20 | 14 | none | 0 | none | 7 | 1 | 2 | 1 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 6 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Nankai University天津市人民医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Teaching Hospital, Tianjin University of Traditional Chinese Medicine天津中医药大学第一附属医院 | none | none | none | none | 264 open | none | 54 open | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Haihe Hospital天津市海河医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所) | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 4728 open | 1312 open | 489 open | none | 3432 open | 1 | 255 open | none | 0 | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | 1 | none | none | none | 0 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Pingjin Hospital平津医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine天津中医药大学第二附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Hospital of Tianjin Medical University天津医科大学第二医院 | none | none | none | 3 | 8 | none | none | none | none | none | none | 0 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 23 | 4 | none | none | none | none | 1 | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| TEDA International Cardiovascular Hospital泰达国际心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | 15 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| TEDA International Cardiovascular Hospital泰达国际心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Baodi Hospital天津市宝坻区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Chest Hospital天津市胸科医院 | none | none | none | none | 39 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 362 open | 4 | none | none | none | none | 3 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Children's Hospital天津市儿童医院 | none | none | none | none | none | none | none | none | 2 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 17 | none | none | none | none | none | none | none | none | none | none | 0 | none | 2 | none | none | 0 | none | none | none | none | none | 1 | 2 | none | none | none | none | none | none | none | |
| Tianjin Eye Hospital天津市眼科医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Fifth Central Hospital天津市第五中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin First Central Hospital天津市第一中心医院 | none | none | 45 | none | 191 open | none | none | none | 1 | none | 1 | 3 | 0 | 0 | none | 8 | 2 | none | none | 21 | none | none | none | 0 | none | none | none | none | none | none | 9 | 3 | 3 | none | none | 1 | none | 2 | none | 0 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Fourth Central Hospital天津市第四中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Hospital天津市天津医院 | none | none | none | none | none | none | none | none | none | none | none | 10 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | 1 | none | none | none | none | none | none | 0 | none | 1 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Huanhu Hospital天津市环湖医院 | none | none | none | none | none | none | none | 151 open | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 12 open | none | 02 open | none | none | none | none | none | none | 2 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Jinnan Hospital天津市津南医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Medical University Baodi Hospital天津医科大学附属宝坻医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院 | 7 | 4712 open | 8811 open | 786 open | 25830 open | 7112 open | 24617 open | 14 | 1 | none | 1 | 18 | 2 | 211 open | 1 | 101 open | none | none | none | 569 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Tianjin Medical University Eye Hospital天津医科大学眼科医院 | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Medical University General Hospital天津医科大学总医院 | 1 | 5 | 22 | 30 | 124 | 10 | 20 | 783 open | 1 | 1 | none | 3 | 2 | 0 | none | 271 open | 01 open | 23 | none | 71 open | none | none | none | 1 | none | 222 open | 3 | 211 open | 2 | none | none | 16 | 1 | none | none | 0 | none | 7 | none | 1 | 1 | none | none | 2 | none | 1 | 10 | none | none | 4 | 7 | 1 | none | 0 | none | none | 0 | 3 | none | none | none | |
| Tianjin Nankai Hospital天津市南开医院 | none | none | none | none | none | 7 | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Port Hospital天津港口医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Second People's Hospital天津市第二人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | |
| Tianjin Third Central Hospital天津市第三中心医院 | none | none | 30 | none | none | none | none | none | none | none | none | 0 | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Traditional Chinese Medicine Affiliated Hospital天津市中医药研究院附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Tianjin.
- Neuroblastoma 1
- Multiple myeloma 4728 open
- B-cell acute lymphoblastic leukaemia 1312 open
- Aplastic anaemia 489 open
- Lymphoma 3432 open
- Beta thalassaemia 1
- Haemophilia A 255 open
- Thrombotic thrombocytopenic purpura 0
- Fanconi anaemia 3
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 1
- Gaucher disease 0
- Primary sclerosing cholangitis 1
- Hepatocellular carcinoma 45
- Lung cancer 191 open
- Hepatoblastoma 1
- Chordoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 0
- Neuroblastoma 0
- Multiple myeloma 8
- B-cell acute lymphoblastic leukaemia 2
- Lymphoma 21
- Thrombotic thrombocytopenic purpura 0
- Biliary atresia 9
- Coronary heart disease 3
- Congenital heart disease 3
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 0
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 7
- Oesophageal squamous cell carcinoma 4712 open
- Hepatocellular carcinoma 8811 open
- Stomach cancer 786 open
- Lung cancer 25830 open
- Pancreatic cancer 7112 open
- Breast cancer 24617 open
- Glioma 14
- Hepatoblastoma 1
- Chordoma 1
- Osteosarcoma 18
- Gastrointestinal stromal tumour 2
- Neuroblastoma 211 open
- Ewing sarcoma 1
- Multiple myeloma 101 open
- Lymphoma 569 open
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 1
- Oesophageal squamous cell carcinoma 5
- Hepatocellular carcinoma 22
- Stomach cancer 30
- Lung cancer 124
- Pancreatic cancer 10
- Breast cancer 20
- Glioma 783 open
- Hepatoblastoma 1
- Retinoblastoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 2
- Neuroblastoma 0
- Multiple myeloma 271 open
- B-cell acute lymphoblastic leukaemia 01 open
- Aplastic anaemia 23
- Lymphoma 71 open
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 222 open
- IgG4-related disease 3
- Myasthenia gravis 211 open
- Moyamoya disease 2
- Coronary heart disease 16
- Congenital heart disease 1
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 7
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 1
- Duchenne muscular dystrophy 2
- Alport syndrome 1
- IgA nephropathy 10
- Osteogenesis imperfecta 4
- Primary biliary cholangitis 7
- Primary sclerosing cholangitis 1
- Hirschsprung disease 0
- Familial adenomatous polyposis 0
- Leber hereditary optic neuropathy 3
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Tianjin on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.